Holen Sie sich die Stockscreener-App
0.8144
1.42%
0.0114
Handel nachbörslich:
.78
-0.0344
-4.22%
Schlusskurs vom Vortag:
$0.803
Offen:
$0.84
24-Stunden-Volumen:
149.02K
Relative Volume:
0.08
Marktkapitalisierung:
$3.08M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-120.30K
KGV:
-1.4805
EPS:
-0.5501
Netto-Cashflow:
$-7.29M
1W Leistung:
-21.69%
1M Leistung:
-11.48%
6M Leistung:
-59.68%
1J Leistung:
-95.76%
1-Tages-Spanne:
$0.78
$0.84
1-Wochen-Bereich:
$0.7765
$1.03
52-Wochen-Spanne:
$0.702
$25.26
Revelation Biosciences Inc Stock (REVB) Company Profile
Firmenname
Revelation Biosciences Inc
Sektor
Branche
Telefon
650-800-3717
Adresse
4660 LAJOLLA VILLAGE DRIVE, SAN DIEGO
Vergleichen Sie REVB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| REVB | 0.8144 | 3.08M | 0 | -120.30K | -7.29M | -0.5501 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Revelation Biosciences Inc Aktie (REVB) Neueste Nachrichten
Revelation Biosciences, Inc. Completes the GMP Manufacture of Gemini Clinical Drug Supply - BioSpace
Revelation Bio Achieves Key Manufacturing Milestone for Kidney Disease Drug Trial | REVB Stock News - StockTitan
United Therapeutics (UTHR) Stock Dips Amid Broader Biotech Indus - GuruFocus.com
Allergic Rhinitis Treatment Market Size in the 7MM is expected to Grow by 2034 | DelveInsight - Barchart
REVB: Good Expense Control as Company Prepares for Trials - Research Tree
Pre-market Movers: REVB, CDIO, SMLR, DWTX... - RTTNews
Why Revelation Biosciences Shares Are Trading Higher By Around 49%; Here Are 20 Stocks Moving Premarket - Benzinga
REVB Results Set Stage for Future Growth - Yahoo Finance
Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2024 - sharewise
Revelation Biosciences Inc expected to post a loss of $2.29 a shareEarnings Preview - XM
Revelation Bio Q3 Loss Narrows to $2.2M, Secures $3.8M from Warrants Amid Cash Decline | REVB Stock News - StockTitan
Revelation Biosciences Inc (REVB) Quarterly 10-Q Report - Quartzy
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.14% - MSN
Revelation Biosciences faces Nasdaq delisting over noncompliance - Investing.com India
United States shares lower at close of trade; Dow Jones Industrial Average down 0.43% - MSN
ROTH to Host 3rd Annual Healthcare Opportunities Conference on October 9 in New York City - The Manila Times
A better buy-in window may exist right now for Revelation Biosciences Inc (REVB) - SETE News
Revelation Biosciences Inc Inc. (REVB) Price Performance: A Guide to Technical Indicators - The InvestChronicle
Farallon Capital Management LLC Boosts Stake in Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat
Revolution Medicines added to Analyst Focus List at JPMorgan - TipRanks
Revelation Biosciences’ Gemini Induces Dose Dependent Significant Increases in IL-10 - Morningstar
Revolution Medicines, Inc. (NASDAQ:RVMD) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Revolution Medicines (NASDAQ:RVMD) Trading Down 6.1% - MarketBeat
A stock that deserves closer examination: Revelation Biosciences Inc (REVB) - US Post News
Revance Therapeutics Shares Fall on Crown Labs Deal Delay - MarketWatch
Financial Fitness Check: Examining Revelation Biosciences Inc (REVB)’s Key Ratios - The Dwinnex
Revance Therapeutics plunges as Crown Labs tender offer delayed amid Teoxane dispute - Seeking Alpha
Revolve Group (NYSE:RVLV) Reaches New 1-Year High at $25.96 - Defense World
Revelation Biosciences stock hits 52-week low at $0.78 - Investing.com India
Revelation Biosciences stock hits 52-week low at $0.78 By Investing.com - Investing.com Australia
Revolution Medicines executive sells over $500k in company stock By Investing.com - Investing.com Canada
Revolution Medicines COO sells over $191k in company stock By Investing.com - Investing.com Canada
Revolution Medicines CFO sells over $99k in company stock - Investing.com India
Revolution Medicines executive sells over $200k in company stock - Investing.com
Revolution Medicines general counsel sells shares worth over $64k By Investing.com - Investing.com UK
Renovaro faces Nasdaq delisting over share price woes By Investing.com - Investing.com Australia
The growth track for Revolution Medicines Inc (RVMD) has changed recently - SETE News
Crown Labs tender offer for Revance delayed, expect deal to be completedanalyst - MSN
Revelation Pharma Announces Revelation Wholesale, an Extension of Its National Compounding Network - PR Newswire
455,099 Shares in Revolution Medicines, Inc. (NASDAQ:RVMD) Bought by Sofinnova Investments Inc. - MarketBeat
Revolve Group (NYSE:RVLV) Trading Down 5.2% - MarketBeat
Revance Therapeutics falls as Crown Labs didn't start tender offer by deadline (update) - Seeking Alpha
RVLV stock soars to 52-week high, touches $24.67 - Investing.com
Financial Metrics Check: Revelation Biosciences Inc (REVB)’s Ratios for Trailing Twelve Months - The Dwinnex
United States shares higher at close of trade; Dow Jones Industrial Average up 0.14% - MSN
Revelation Biosciences announces warrant exercise and inducement - Investing.com India
Revelation Biosciences Inc. Announces Exercise of Warrants for $3.8 Million in Gross Proceeds - Manchestertimes
Stock Performance Spotlight: Revelation Biosciences Inc (REVB) Ends the Day at 1.25, Down by -40.19 - The Dwinnex
Nasdaq Down Over 200 Points; Williams-Sonoma Shares Tumble After Q2 Results - Benzinga
Gold Down Over 1%; US Initial Jobless Claims Increase - Benzinga
Revelation Biosciences Inc [REVB] Stock trading around $2.09 per share: What’s Next? - The DBT News
Finanzdaten der Revelation Biosciences Inc-Aktie (REVB)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):